ArticleEuropean journal of nuclear medicine and molecular imaging2021
Diagnostic performance of
Article in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03187990 (Single-center Study for Biopsy Guidance Using Gallium-68 Labeled Prostate-specific Membrane Antigen), which is not on this map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Single-center Study for Biopsy Guidance Using Gallium-68 Labeled Prostate-specific Membrane Antigen (PSMA) PET/MRI in Patients With Elevated PSA Eligible for Prostate Biopsy in Comparison to Multiparametric MRI.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.
- PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.European journal of nuclear medicine and molecular imaging · 2023Guideline
- Transrectal Ultrasound-Guided Prostate Biopsy with and without PSMA-PET-Targeted Prostate Biopsy for Prostate Cancer Diagnosis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Feasibility and early outcomes of salvage robot-assisted radical prostatectomy after focal therapy failure for localized prostate cancer.Translational andrology and urology · 2026Article
- PSMA PET: the answer to MRI-occult prostate cancer… or another mirage?European radiology · 2026Review
- Can chatGPT-4o reliably standardize PSMA PET/CT and PET/MRI reports using PROMISE V2 criteria? - An exploratory study.EJNMMI research · 2026Article
- Development and validation of prostate-specific membrane antigen-adjusted Prostate Imaging Reporting and Data System: A new approach to enhancing the accuracy of diagnosing treatment-naïve primary prostate cancer.Asian journal of urology · 2026Article
- Multimodal data fusion: integrating PET/MRI and liquid biopsy for a holistic view of cancer biology.Frontiers in oncology · 2026Review
- Dutasteride treatment and its effect on standardized uptake values in prostate-specific membrane antigen-PET imaging: A pilot study.PloS one · 2026Article
- Machine learning-based construction and validation of an radiomics model for predicting ISUP grading in prostate cancer: a multicenter radiomics study based on [68Ga]Ga-PSMA PET/CT.European journal of nuclear medicine and molecular imaging · 2025Article
- Localization of PSMA-avid lesions on PSMA PET-CT on prostate MRI in patients with PI-RADS 3.Abdominal radiology (New York) · 2025Article
- Comparative Analysis ofAdvances in radiation oncology · 2025Article
- The evolving role of positron emission tomography in precision prostate cancer biopsy.European journal of clinical investigation · 2025Review
- A Robust [Journal of imaging informatics in medicine · 2025Article
- Multimodal radiomics based on fluorine-18 prostate-specific membrane antigen positron emission tomography and multiparametric magnetic resonance imaging in predicting persistent prostate-specific antigen after radical prostatectomy.Quantitative imaging in medicine and surgery · 2025Article
- Exploring the Correlation Between Multiparameters Detected in Primary Prostate Cancer using F‑18 PSMA‑1007 PET/MRI and their Potential for Predicting Metastasis.Nuclear medicine and molecular imaging · 2025Article
- Comparison betweenAsian journal of urology · 2025Article
- A Pilot Study of PSMA PET/CT and MRI Fusion for Prostate Cancer: Software to Replace PET/MRI Hardware.Journal of clinical medicine · 2024Article
- Enhancing the diagnostic capacity of [EJNMMI reports · 2024Article
- The first-in-human preclinical evaluation of the new probe [123I]I-PSMA-7 for real-time intraoperative targeted biopsy and SPECT/CT imaging in prostate cancer.European journal of nuclear medicine and molecular imaging · 2024Article
- PSMA-positive prostatic volume prediction with deep learning based on T2-weighted MRI.La Radiologia medica · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 3 countries.
Funding
Abstract
purposeUltrasound-guided biopsy (US biopsy) with 10-12 cores has a suboptimal sensitivity for clinically significant prostate cancer (sigPCa). If US biopsy is negative, magnetic resonance imaging (MRI)-guided biopsy is recommended, despite a low specificity for lesions with score 3-5 on Prostate Imaging Reporting and Data System (PIRADS). Screening and biopsy guidance using an imaging modality with high accuracy could reduce the number of unnecessary biopsies, reducing side effects. The aim of this study was to assess the performance of positron emission tomography/MRI with
methodsProspective, open-label, single-center, non-randomized, diagnostic accuracy study including patients with suspected PCa by elevation of prostate-specific antigen (PSA) level and a suspicious lesion (PIRADS ≥3) on multiparametric MRI (mpMRI). Forty-two patients underwent PSMA-PET/MRI followed by both PSMA-PET/MRI-guided and section-based saturation template biopsy between May 2017 and February 2019. Primary outcome was the accuracy of PSMA-PET/MRI for biopsy guidance using section-based saturation template biopsy as the reference standard.
resultsSigPCa was found in 62% of the patients. Patient-based sensitivity, specificity, negative and positive predictive value, and accuracy for sigPCa were 96%, 81%, 93%, 89%, and 90%, respectively. One patient had PSMA-negative sigPCa. Eight of nine false-positive lesions corresponded to cancer on prostatectomy and one in six false-negative lesions was negative on prostatectomy.
conclusionPSMA-PET/MRI has a high accuracy for detecting sigPCa and is a promising tool to select patients with suspicion of PCa for biopsy.
trial registrationThis trial was retrospectively registered under the name "Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) Guided Biopsy in Men with Elevated PSA" (NCT03187990) on 06/15/2017 ( https://clinicaltrials.gov/ct2/show/NCT03187990 ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.